RecruitingNCT03481881

Pharmacokinetics of Drugs Administered to Children

Pharmacokinetics of Drugs Administered to Children Per Standard of Care

Sponsor

Duke University

Enrollment

200 participants

Start Date

Aug 14, 2013

Study Type

OBSERVATIONAL

Conditions

Pediatric ALL

Summary

This is a prospective study of children \<21 years of age with the goal of characterizing the PK of drugs administered per standard of care as prescribed by the treating caregiver.

Eligibility

Min Age: 0 YearsMax Age: 20 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting blood samples from children and young people under 21 years of age who are already receiving certain medications as part of their normal medical care, to study how children's bodies process and respond to these drugs differently than adults — information that is currently very limited for many medicines used in pediatrics. **You may be eligible if...** - Your child is under 21 years of age - Your child is currently receiving one of the specific understudied medications as part of their standard medical care (prescribed by their treating doctor) **You may NOT be eligible if...** - Consent or assent (agreement from the child, if old enough) cannot be obtained from the parent/guardian and patient Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGStandard of care drug

This study is collecting PK data on children prescribed the following drugs of interest per standard of care: dexmedetomidine, bosentan, furosemide, chlorothiazide, ethacrynic acid, bumetanide, hydromorphone, tacrolimus, ampicillin, gentamicin, caffeine, fentanyl, midazolam, foscarnet, hydroxychloroquine, and moxifloxacin.